WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522374
Description: ABE171, also known as NVP-ABE171, is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities. NVP-ABE171 inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D with respective IC(50) values of 602, 34, 1230, and 1.5 nM. In human cells, NVP-ABE171 inhibited the eosinophil and neutrophil oxidative burst, the release of cytokines by T cells, and the tumor necrosis factor-alpha release from monocytes, in the nanomolar range. NVP-ABE171 inhibited the airway neutrophil influx and activation with an ED(50) in the range of 3 mg/kg. NVP-ABE171 shows activity both in vitro on human inflammatory cells and in vivo in animal models of lung inflammation.
MedKoo Cat#: 522374
Chemical Formula: C21H12N4O3
Exact Mass: 368.09094
Molecular Weight: 368.35
Elemental Analysis: C, 68.48; H, 3.28; N, 15.21; O, 13.03
ABE171 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: ABE171; ABE-171; ABE 171; NVP-ABE171; NVP-ABE-171; NVP-ABE 171.
IUPAC/Chemical Name: 4-(8-(benzo[c][1,2,5]oxadiazol-5-yl)-1,7-naphthyridin-6-yl)benzoic acid
InChi Key: IALXIRPKVRUJQO-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H12N4O3/c26-21(27)13-5-3-12(4-6-13)17-10-14-2-1-9-22-19(14)20(23-17)15-7-8-16-18(11-15)25-28-24-16/h1-11H,(H,26,27)
SMILES Code: O=C(O)C1=CC=C(C2=NC(C3=CC4=NON=C4C=C3)=C5N=CC=CC5=C2)C=C1
The following data is based on the product molecular weight 368.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W,
Beebe DJ, Marker PC. Phosphodiesterase 4D inhibitors limit prostate cancer growth
potential. Mol Cancer Res. 2015 Jan;13(1):149-60. doi:
10.1158/1541-7786.MCR-14-0110. Epub 2014 Aug 22. PubMed PMID: 25149359; PubMed
Central PMCID: PMC4312503.
2: Tigani B, Cannet C, Zurbrugg S, Schaeublin E, Mazzoni L, Fozard JR, Beckmann
N. Resolution of the oedema associated with allergic pulmonary inflammation in
rats assessed noninvasively by magnetic resonance imaging. Br J Pharmacol. 2003
Sep;140(2):239-46. Epub 2003 Aug 18. PubMed PMID: 12970099; PubMed Central PMCID:
3: Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R. Pharmacological
profile of a novel phosphodiesterase 4 inhibitor,
(NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities.
J Pharmacol Exp Ther. 2002 Apr;301(1):241-8. PubMed PMID: 11907180.